New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
06:21 EDTCADX, BMY, BAXCadence announces supply agreement with Laboratorios Grifols
Cadence Pharmaceuticals (CADX) announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV injection in flexible plastic bags. Previously, Cadence announced the extension of its supply arrangement for OFIRMEV in glass vials with Lawrence Laboratories, a member of the Bristol Myers Squibb (BMY) group of companies, through December 31, 2018. Additionally, the company has terminated its development and supply agreement for OFIRMEV in glass vials with Baxter Healthcare Corporation (BAX).
News For CADX;BMY;BAX From The Last 14 Days
Check below for free stories on CADX;BMY;BAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
14:00 EDTBAXBaxter, Halozyme announce favorable FDA panel recommendation on HyQvia
Subscribe for More Information
12:39 EDTBAXFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
Subscribe for More Information
07:10 EDTBAXFDA Blood Products Advisory Committee to hold a meeting
Subscribe for More Information
06:10 EDTBMYEli Lilly downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Eli Lilly (LLY) to Neutral saying Alimta upside and the company's pipeline is largely priced into shares at current levels. Citi raised its price target for Lilly shares to $66 from $60 and said it prefers Bristol-Myers (BMY) and Pfizer (PFE) in the U.S.
July 30, 2014
08:08 EDTBAXBaxter announces divestiture of commercial vaccines business to Pfizer for $635M
Baxter International (BAX) announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer (PFE) for a total cash consideration of $635M, subject to certain adjustments. The sale includes the company’s commercial vaccines business, which is comprised of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis, an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. Both vaccines are currently available outside the United States, primarily in a number of European markets. Baxter continues to explore strategic options, including the potential for partnering or divesting its R&D development programs focused on influenza and Lyme disease. Subject to regulatory approvals and other customary closing conditions, the companies expect to close the transaction by the end of 2014. Baxter expects 2014 vaccines revenues to total approximately $300M and adjusted earnings of approximately 25c per diluted share, including approximately $50M of one-time milestone payments related to the ongoing government collaborations for development of influenza vaccines. Baxter expects the transaction to be modestly dilutive to fourth quarter 2014 adjusted earnings and dilutive to 2015 adjusted earnings by approximately 15c per diluted share.
08:01 EDTBAXPfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
Subscribe for More Information
July 29, 2014
07:09 EDTBMYBristol-Myers, Pfizer granted EU approval for Eliquis for treatment of DVT, PE
Subscribe for More Information
July 25, 2014
07:27 EDTBMYEMA recommends expanded indication for Baraclude
Subscribe for More Information
06:00 EDTBMYBristol-Myers implied volatility of 17 at lower end of index mean range
Subscribe for More Information
July 24, 2014
11:22 EDTBMYBristol-Myers says considering different sizes of deal opportunities
Subscribe for More Information
10:57 EDTBMYBristol-Myers says M&A would have to be good strategic fit
Subscribe for More Information
10:48 EDTBMYBristol-Myers says guidance assumes R&D credit will be extended
Says Reyataz seeing increased competitive pressure. Says business development a top priority for capital allocation. Comments made on the Q2 earnings conference call.
08:28 EDTBMYBristol-Myers management to meet with JPMorgan
Subscribe for More Information
07:32 EDTBMYBristol-Myers reaffirms 2014 EPS outlook $1.70-$1.80, consensus $1.77
Subscribe for More Information
07:31 EDTBMYBristol-Myers reports Q2 EPS 48c, consensus 44c
Reports Q2 revenue $ $3.89B, consensus $3.85B.
05:26 EDTBMYBristol-Myers, Ono Pharmaceutical announces strategic collaboration in Japan
Bristol-Myers Squibb and Ono Pharmaceutical have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. As part of the agreement, Bristol-Myers Squibb and Ono will jointly develop and commercialize Opdivo and Yervoy across a broad range of tumor types. Bristol-Myers Squibb and Ono will jointly pursue development of monotherapy and combination regimens, with Opdivo as the foundational therapy in Japan, South Korea and Taiwan, and leverage global clinical trials by including patients from the three countries.
July 23, 2014
15:30 EDTBMYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
15:10 EDTBMYBristol-Myers technical comments before earnings
Subscribe for More Information
July 21, 2014
06:43 EDTBMYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use